Designing and building the next generation of improved vaccine adjuvants

Journal of Controlled Release

Volumn 190, Issue , 2014, Pages 563-579

  Brito, Luis A ^a   O'Hagan, Derek T ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (United States)

Author keywords

Adjuvants; Alum; Emulsions; Liposomes; PLG; TLR

Indexed keywords

ANTIGENS; CELL MEMBRANES; CYTOLOGY; EMULSIONS; LIPOSOMES; NUCLEIC ACIDS;

ADJUVANTS; ALUM; MEMBRANE COMPONENTS; PHARMACEUTICAL SCIENCE; PLG; POLYMERIC PARTICLES; TLR; VACCINE ADJUVANTS;

VACCINES;

ALUMINUM POTASSIUM SULFATE; ANTIGEN; ISCOM; LIPOSOME; NANOPARTICLE; POLYMER; VACCINE; ALUMINUM SALT; IMIQUIMOD; MIFAMURTIDE; POLYINOSINIC POLYCYTIDYLIC ACID; VIROSOME; VIROSOME VACCINE; ALUMINUM SULFATE; DELAYED RELEASE FORMULATION; EMULSION; IMMUNOLOGICAL ADJUVANT;

DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG POTENTIATION; DRUG TARGETING; EMULSION; HUMAN; LIPOSOMAL DELIVERY; NONHUMAN; PRIORITY JOURNAL; REVIEW; ADAPTIVE IMMUNITY; ADJUVANT THERAPY; DENDRITIC CELL; EOSINOPHIL; HEPATITIS B VIRUS; IMMUNOCOMPETENT CELL; IN VITRO STUDY; INNATE IMMUNITY; MOLECULAR WEIGHT; MONOCYTE; NEUTROPHIL; POLYMERIZATION; VACCINATION; VIRUS LIKE AGENT; WART VIRUS; DELAYED RELEASE FORMULATION; HISTORY; IMMUNOLOGY;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; EMULSIONS; HISTORY, 20TH CENTURY; HUMANS; LIPOSOMES; NANOPARTICLES; VACCINES;

EID: 84906785463     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.06.027     Document Type: Review

References (192)

1. B.E. Correia, J.T. Bates, R.J. Loomis, G. Baneyx, C. Carrico, J.G. Jardine, P. Rupert, C. Correnti, O. Kalyuzhniy, V. Vittal, M.J. Connell, E. Stevens, A. Schroeter, M. Chen, S. Macpherson, A.M. Serra, Y. Adachi, M.A. Holmes, Y. Li, R.E. Klevit, B.S. Graham, R.T. Wyatt, D. Baker, R.K. Strong, J.E. Crowe Jr., P.R. Johnson, and W.R. Schief Proof of principle for epitope-focused vaccine design Nature 507 2014 201 206
2. J.S. McLellan, M. Chen, M.G. Joyce, M. Sastry, G.B. Stewart-Jones, Y. Yang, B. Zhang, L. Chen, S. Srivatsan, A. Zheng, T. Zhou, K.W. Graepel, A. Kumar, S. Moin, J.C. Boyington, G.Y. Chuang, C. Soto, U. Baxa, A.Q. Bakker, H. Spits, T. Beaumont, Z. Zheng, N. Xia, S.Y. Ko, J.P. Todd, S. Rao, B.S. Graham, and P.D. Kwong Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus Science 342 2013 592 598
3. D. Maione, I. Margarit, C.D. Rinaudo, V. Masignani, M. Mora, M. Scarselli, H. Tettelin, C. Brettoni, E.T. Iacobini, R. Rosini, N. D'Agostino, L. Miorin, S. Buccato, M. Mariani, G. Galli, R. Nogarotto, V. Nardi-Dei, F. Vegni, C. Fraser, G. Mancuso, G. Teti, L.C. Madoff, L.C. Paoletti, R. Rappuoli, D.L. Kasper, J.L. Telford, and G. Grandi Identification of a universal group B streptococcus vaccine by multiple genome screen Science 309 2005 148 150 (Pubitemid 40934997)
4. M. Pizza, V. Scarlato, V. Masignani, M.M. Giuliani, B. Arico, M. Comanducci, G.T. Jennings, L. Baldi, E. Bartolini, B. Capecchi, C.L. Galeotti, E. Luzzi, R. Manetti, E. Marchetti, M. Mora, S. Nuti, G. Ratti, L. Santini, S. Savino, M. Scarselli, E. Storni, P. Zuo, M. Broeker, E. Hundt, B. Knapp, E. Blair, T. Mason, H. Tettelin, D.W. Hood, A.C. Jeffries, N.J. Saunders, D.M. Granoff, J.C. Venter, E.R. Moxon, G. Grandi, and R. Rappuoli Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing Science 287 2000 1816 1820 (Pubitemid 30143965)
5. D.T. O'Hagan, and E. De Gregorio The path to a successful vaccine adjuvant - 'the long and winding road' Drug Discov. Today 14 2009 541 551
6. L.A. Brito, P. Malyala, and D.T. O'Hagan Vaccine adjuvant formulations: a pharmaceutical perspective Semin. Immunol. 25 2013 130 145
7. D.T. O'Hagan, G.S. Ott, G.V. Nest, R. Rappuoli, and G.D. Giudice The history of MF59((R)) adjuvant: a phoenix that arose from the ashes Expert. Rev. Vaccines 12 2013 13 30
8. M. Kanekiyo, C.J. Wei, H.M. Yassine, P.M. McTamney, J.C. Boyington, J.R. Whittle, S.S. Rao, W.P. Kong, L. Wang, and G.J. Nabel Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies Nature 499 2013 102 106
9. A. Roldao, M.C. Mellado, L.R. Castilho, M.J. Carrondo, and P.M. Alves Virus-like particles in vaccine development Expert. Rev. Vaccines 9 2010 1149 1176
10. S.A. Plotkin Correlates of protection induced by vaccination Clin. Vaccine Immunol. 17 2010 1055 1065
11. D. Schenten, and R. Medzhitov The control of adaptive immune responses by the innate immune system Adv. Immunol. 109 2011 87 124
12. E. Meylan, J. Tschopp, and M. Karin Intracellular pattern recognition receptors in the host response Nature 442 2006 39 44 (Pubitemid 44064203)
13. E.M. Moresco, D. LaVine, and B. Beutler Toll-like receptors Curr. Biol. 21 2011 R488 R493
14. B. Beutler, A.J. Hoffman, and M. Steinman The Nobel Prize in Physiology or Medicine 2011 2011
15. D.R. Flower Systematic identification of small molecule adjuvants Expert Opin. Drug Discov. 7 2012 807 817
16. N.W. Baylor, W. Egan, and P. Richman Aluminum salts in vaccines - US perspective Vaccine 20 Suppl. 3 2002 S18 S23 (Pubitemid 34607671)
17. H. Hogenesch Mechanism of immunopotentiation and safety of aluminum adjuvants Front. Immunol. 3 2012 406
18. N. Garcon, S. Morel, A. Didierlaurent, D. Descamps, M. Wettendorff, and M. Van Mechelen Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach BioDrugs 25 2011 217 226
19. A.T. Glenny, and C.G. Pope The antigenic effect of intravenous injection of diphtheria toxin J. Pathol. Bacteriol. 28 1925 273 278
20. V.K. Volk, and W.E. Bunney Diphtheria immunization with fluid toxoid and alum-precipitated toxoid Am. J. Public Health Nations Health 32 1942 690 699
21. F.G. Jones, and J.H. Moss The antitoxic titer of human subjects following immunization with tetanus toxoid and tetanus alum precipitated toxoid J. Immunol. 30 1936 115 125
22. C.T. Johnston, S.L. Wang, and S.L. Hem Measuring the surface area of aluminum hydroxide adjuvant J. Pharm. Sci. 91 2002 1702 1706 (Pubitemid 34680233)
23. M.J. Caulfield, L. Shi, S. Wang, B. Wang, T.W. Tobery, H. Mach, P.L. Ahl, J.L. Cannon, J.C. Cook, J.H. Heinrichs, and R.D. Sitrin Effect of alternative aluminum adjuvants on the absorption and immunogenicity of HPV16 L1 VLPs in mice Hum. Vaccin. 3 2007 139 145 (Pubitemid 47501033)
24. D.W. Cain, S.E. Sanders, M.M. Cunningham, and G. Kelsoe Disparate adjuvant properties among three formulations of "alum" Vaccine 31 2013 653 660
25. S.L. Hem, and H. Hogenesch Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation Expert. Rev. Vaccines 6 2007 685 698 (Pubitemid 47607846)
26. B. Hansen, M. Belfast, G. Soung, L. Song, P.M. Egan, R. Capen, H. Hogenesch, R. Mancinelli, and S.L. Hem Effect of the strength of adsorption of hepatitis B surface antigen to aluminum hydroxide adjuvant on the immune response Vaccine 27 2009 888 892
27. M. Regnier, B. Metz, W. Tilstra, C. Hendriksen, W. Jiskoot, W. Norde, and G. Kersten Structural perturbation of diphtheria toxoid upon adsorption to aluminium hydroxide adjuvant Vaccine 30 2012 6783 6788
28. S. Vecchi, S. Bufali, D.A. Skibinski, D.T. O'Hagan, and M. Singh Aluminum adjuvant dose guidelines in vaccine formulation for preclinical evaluations J. Pharm. Sci. 101 2012 17 20
29. M. Ugozzoli, D. Laera, S. Nuti, D.A. Skibinski, S. Bufali, C. Sammicheli, S. Tavarini, M. Singh, and D.T. O'Hagan Flow cytometry: an alternative method for direct quantification of antigens adsorbed to aluminum hydroxide adjuvant Anal. Biochem. 418 2011 224 230
30. L.J. Peek, T.T. Martin, C. Elk Nation, S.A. Pegram, and C.R. Middaugh Effects of stabilizers on the destabilization of proteins upon adsorption to aluminum salt adjuvants J. Pharm. Sci. 96 2007 547 557 (Pubitemid 46466077)
31. S.F. Ausar, J. Chan, W. Hoque, O. James, K. Jayasundara, and K. Harper Application of extrinsic fluorescence spectroscopy for the high throughput formulation screening of aluminum-adjuvanted vaccines J. Pharm. Sci. 100 2011 431 440
32. J.B. Ulmer, C.M. DeWitt, M. Chastain, A. Friedman, J.J. Donnelly, W.L. McClements, M.J. Caulfield, K.E. Bohannon, D.B. Volkin, and R.K. Evans Enhancement of DNA vaccine potency using conventional aluminum adjuvants Vaccine 18 1999 18 28 (Pubitemid 29432134)
33. P. Marrack, A.S. McKee, and M.W. Munks Towards an understanding of the adjuvant action of aluminium Nat. Rev. Immunol. 9 2009 287 293
34. M. Kool, K. Fierens, and B.N. Lambrecht Alum adjuvant: some of the tricks of the oldest adjuvant J. Med. Microbiol. 61 2012 927 934
35. E. De Gregorio, E. Caproni, and J.B. Ulmer Vaccine adjuvants: mode of action Front. Immunol. 4 2013 214
36. A.T. Glenny, G.A.H. Buttle, and M.F. Stevens Rate of disappearance of diphtheria toxoid injected into rabbits and guinea-pigs: toxoid precipitated with alum J. Pathol. Bacteriol. 34 1931 267 275
37. W.T. Harrison Some observations on the use of alum precipitated diphtheria toxoid Am. J. Public Health Nations Health 25 1935 298 300
38. L.B. Holt Quantitative studies in diphtheria prophylaxis: the second response Br. J. Exp. Pathol. 31 1950 233 241
39. R.G. White, A.H. Coons, and J.M. Connolly Studies on antibody production. III. The alum granuloma J. Exp. Med. 102 1955 73 82
40. 14C-labeled tetanus toxoid Vaccine 14 1996 1412 1416 (Pubitemid 27010310)
41. S. Hutchison, R. Benson, V. Gibson, A. Pollock, P. Garside, and J. Brewer Antigen depot is not required for alum adjuvanticity FASEB J. 26 2012 1272 1279
42. F. Verdier, R. Burnett, C. Michelet-Habchi, P. Moretto, F. Fievet-Groyne, and E. Sauzeat Aluminium assay and evaluation of the local reaction at several time points after intramuscular administration of aluminium containing vaccines in the cynomolgus monkey Vaccine 23 2005 1359 1367 (Pubitemid 40127328)
43. J.L. Leeling, I.A. Muni, R.J. Helms, and N. Johnson Jr. Rates of release of subcutaneously injected antigens in the rat, comparison of an aqueous preparation with two alum-precipitated preparations Allergy 34 1979 339 344 (Pubitemid 10206397)
44. S.M. Noe, M.A. Green, H. HogenEsch, and S.L. Hem Mechanism of immunopotentiation by aluminum-containing adjuvants elucidated by the relationship between antigen retention at the inoculation site and the immune response Vaccine 28 2010 3588 3594
45. N. Goto, H. Kato, J. Maeyama, M. Shibano, T. Saito, J. Yamaguchi, and S. Yoshihara Local tissue irritating effects and adjuvant activities of calcium phosphate and aluminium hydroxide with different physical properties Vaccine 15 1997 1364 1371 (Pubitemid 27397815)
46. M. Kool, T. Soullie, M. van Nimwegen, M.A. Willart, F. Muskens, S. Jung, H.C. Hoogsteden, H. Hammad, and B.N. Lambrecht Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells J. Exp. Med. 205 2008 869 882 (Pubitemid 351549884)
47. A.S. McKee, M. MacLeod, J. White, F. Crawford, J.W. Kappler, and P. Marrack Gr1 + IL-4-producing innate cells are induced in response to Th2 stimuli and suppress Th1-dependent antibody responses Int. Immunol. 20 2008 659 669 (Pubitemid 351649184)
48. S. Calabro, M. Tortoli, B.C. Baudner, A. Pacitto, M. Cortese, D.T. O'Hagan, E. De Gregorio, A. Seubert, and A. Wack Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes Vaccine 29 2011 1812 1823
49. J.W. Mannhalter, H.O. Neychev, G.J. Zlabinger, R. Ahmad, and M.M. Eibl Modulation of the human immune response by the non-toxic and non-pyrogenic adjuvant aluminium hydroxide: effect on antigen uptake and antigen presentation Clin. Exp. Immunol. 61 1985 143 151 (Pubitemid 15029859)
50. M. Ulanova, A. Tarkowski, M. Hahn-Zoric, and L.A. Hanson The common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism Infect. Immun. 69 2001 1151 1159 (Pubitemid 32109584)
51. A.C. Rimaniol, G. Gras, F. Verdier, F. Capel, V.B. Grigoriev, F. Porcheray, E. Sauzeat, J.G. Fournier, P. Clayette, C.A. Siegrist, and D. Dormont Aluminum hydroxide adjuvant induces macrophage differentiation towards a specialized antigen-presenting cell type Vaccine 22 2004 3127 3135 (Pubitemid 39037217)
52. R.K. Gupta Aluminum compounds as vaccine adjuvants Adv. Drug Deliv. Rev. 32 1998 155 172 (Pubitemid 28267407)
53. G.L. Morefield, A. Sokolovska, D. Jiang, H. HogenEsch, J.P. Robinson, and S.L. Hem Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro Vaccine 23 2005 1588 1595 (Pubitemid 40203396)
54. F. Mosca, E. Tritto, A. Muzzi, E. Monaci, F. Bagnoli, C. Iavarone, D. O'Hagan, R. Rappuoli, and E. De Gregorio Molecular and cellular signatures of human vaccine adjuvants Proc. Natl. Acad. Sci. U. S. A. 105 2008 10501 10506
55. A.S. McKee, M.W. Munks, M.K. MacLeod, C.J. Fleenor, N. Van Rooijen, J.W. Kappler, and P. Marrack Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity J. Immunol. 183 2009 4403 4414
56. M.F. Bachmann, and G.T. Jennings Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns Nat. Rev. Immunol. 10 2010 787 796
57. H. Liu, K.D. Moynihan, Y. Zheng, G.L. Szeto, A.V. Li, B. Huang, D.S. Van Egeren, C. Park, and D.J. Irvine Structure-based programming of lymph-node targeting in molecular vaccines Nature 507 2014 519 522
58. A. Seubert, E. Monaci, M. Pizza, D.T. O'Hagan, and A. Wack The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells J. Immunol. 180 2008 5402 5412
59. N. Goto, and K. Akama Histopathological studies of reactions in mice injected with aluminum-adsorbed tetanus toxoid Microbiol. Immunol. 26 1982 1121 1132 (Pubitemid 13146183)
60. R.S. Walls Eosinophil response to alum adjuvants: involvement of T cells in non-antigen-dependent mechanisms Proc. Soc. Exp. Biol. Med. 156 1977 431 435 (Pubitemid 8265222)
61. V.D. Ramanathan, P. Badenoch-Jones, and J.L. Turk Complement activation by aluminium and zirconium compounds Immunology 37 1979 881 888 (Pubitemid 9256329)
62. H. Li, S. Nookala, and F. Re Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1beta and IL-18 release J. Immunol. 178 2007 5271 5276 (Pubitemid 46595312)
63. A. Sokolovska, S.L. Hem, and H. HogenEsch Activation of dendritic cells and induction of CD4(+) T cell differentiation by aluminum-containing adjuvants Vaccine 25 2007 4575 4585 (Pubitemid 46734537)
64. A.L. Gavin, K. Hoebe, B. Duong, T. Ota, C. Martin, B. Beutler, and D. Nemazee Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling Science 314 2006 1936 1938 (Pubitemid 46026117)
65. F.A. Sharp, D. Ruane, B. Claass, E. Creagh, J. Harris, P. Malyala, M. Singh, D.T. O'Hagan, V. Petrilli, J. Tschopp, L.A. O'Neill, and E.C. Lavelle Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome Proc. Natl. Acad. Sci. U. S. A. 106 2009 870 875
66. E. De Gregorio, E. Tritto, and R. Rappuoli Alum adjuvanticity: unraveling a century old mystery Eur. J. Immunol. 38 2008 2068 2071
67. T. Marichal, K. Ohata, D. Bedoret, C. Mesnil, C. Sabatel, K. Kobiyama, P. Lekeux, C. Coban, S. Akira, K.J. Ishii, F. Bureau, and C.J. Desmet DNA released from dying host cells mediates aluminum adjuvant activity Nat. Med. 17 2011 996 1002
68. N. Riteau, L. Baron, B. Villeret, N. Guillou, F. Savigny, B. Ryffel, F. Rassendren, M. Le Bert, A. Gombault, and I. Couillin ATP release and purinergic signaling: a common pathway for particle-mediated inflammasome activation Cell Death Dis. 3 2012 e403
69. Y. Wang, D. Rahman, and T. Lehner A comparative study of stress-mediated immunological functions with the adjuvanticity of alum J. Biol. Chem. 287 2012 17152 17160
70. T.L. Flach, G. Ng, A. Hari, M.D. Desrosiers, P. Zhang, S.M. Ward, M.E. Seamone, A. Vilaysane, A.D. Mucsi, Y. Fong, E. Prenner, C.C. Ling, J. Tschopp, D.A. Muruve, M.W. Amrein, and Y. Shi Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity Nat. Med. 17 2011 479 487
71. P. Matzinger Tolerance, danger, and the extended family Annu. Rev. Immunol. 12 1994 991 1045 (Pubitemid 24140436)
72. M.E. Bianchi DAMPs, PAMPs and alarmins: all we need to know about danger J. Leukoc. Biol. 81 2007 1 5 (Pubitemid 46028489)
73. N. Goto, H. Kato, J. Maeyama, M. Shibano, T. Saito, J. Yamaguchi, and S. Yoshihara Local tissue irritating effects and adjuvant activities of calcium phosphate and aluminium hydroxide with different physical properties Vaccine 15 1997 1364 1371 (Pubitemid 27397815)
74. V. Aimanianda, J. Haensler, S. Lacroix-Desmazes, S.V. Kaveri, and J. Bayry Novel cellular and molecular mechanisms of induction of immune responses by aluminum adjuvants Trends Pharmacol. Sci. 30 2009 287 295
75. N. Qureshi, K. Takayama, and E. Ribi Purification and structural determination of nontoxic lipid A obtained from the lipopolysaccharide of Salmonella typhimurium J. Biol. Chem. 257 1982 11808 11815 (Pubitemid 13218648)
76. A.M. Didierlaurent, S. Morel, L. Lockman, S.L. Giannini, M. Bisteau, H. Carlsen, A. Kielland, O. Vosters, N. Vanderheyde, F. Schiavetti, D. Larocque, M. Van Mechelen, and N. Garcon AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity J. Immunol. 183 2009 6186 6197
77. G.E. Mullen, R.D. Ellis, K. Miura, E. Malkin, C. Nolan, M. Hay, M.P. Fay, A. Saul, D. Zhu, K. Rausch, S. Moretz, H. Zhou, C.A. Long, L.H. Miller, and J. Treanor Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria PLoS One 3 2008 e2940
78. J.A. Aebig, G.E. Mullen, G. Dobrescu, K. Rausch, L. Lambert, O. Ajose-Popoola, C.A. Long, A. Saul, and A.P. Miles Formulation of vaccines containing CpG oligonucleotides and alum J. Immunol. Methods 323 2007 139 146 (Pubitemid 46890965)
79. R.L. Coffman, A. Sher, and R.A. Seder Vaccine adjuvants: putting innate immunity to work Immunity 33 2010 492 503
80. H. Hemmi, T. Kaisho, O. Takeuchi, S. Sato, H. Sanjo, K. Hoshino, T. Horiuchi, H. Tomizawa, K. Takeda, and S. Akira Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway Nat. Immunol. 3 2002 196 200 (Pubitemid 34141451)
81. N.M. Valiante Designing Small Molecules as Optimal Vaccine Adjuvants 2014 (in preparation)
82. J.P. Vasilakos, and M.A. Tomai The use of Toll-like receptor 7/8 agonists as vaccine adjuvants Expert. Rev. Vaccines 12 2013 809 819
83. M.R. Hilleman Critical appraisal of emulsified oil adjuvants applied to viral vaccines Prog. Med. Virol. 8 1966 131 182
84. T. Vesikari, M. Knuf, P. Wutzler, A. Karvonen, D. Kieninger-Baum, H.J. Schmitt, F. Baehner, A. Borkowski, T.F. Tsai, and R. Clemens Oil-in-water emulsion adjuvant with influenza vaccine in young children N. Engl. J. Med. 365 2011 1406 1416
85. H. Nohynek, J. Jokinen, M. Partinen, O. Vaarala, T. Kirjavainen, J. Sundman, S.L. Himanen, C. Hublin, I. Julkunen, P. Olsen, O. Saarenpaa-Heikkila, and T. Kilpi AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland PLoS One 7 2012 e33536
86. T.F. Tsai, A. Crucitti, P. Nacci, U. Nicolay, G. Della Cioppa, J. Ferguson, and R. Clemens Explorations of clinical trials and pharmacovigilance databases of MF59(R)-adjuvanted influenza vaccines for associated cases of narcolepsy Scand. J. Infect. Dis. 43 2011 702 706
87. S. Morel, A. Didierlaurent, P. Bourguignon, S. Delhaye, B. Baras, V. Jacob, C. Planty, A. Elouahabi, P. Harvengt, H. Carlsen, A. Kielland, P. Chomez, N. Garcon, and M. Van Mechelen Adjuvant System AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity Vaccine 29 2011 2461 2473
88. D.T. O'Hagan, G.S. Ott, E. De Gregorio, and A. Seubert The mechanism of action of MF59 - an innately attractive adjuvant formulation Vaccine 30 2012 4341 4348
89. G. Ott, G.L. Barchfeld, D. Chernoff, R. Radhakrishnan, P. van Hoogevest, and G. Van Nest MF59. Design and evaluation of a safe and potent adjuvant for human vaccines Pharm. Biotechnol. 6 1995 277 296
90. M. Dupuis, D.M. McDonald, and G. Ott Distribution of adjuvant MF59 and antigen gD2 after intramuscular injection in mice Vaccine 18 1999 434 439 (Pubitemid 29462599)
91. M. Vono, M. Taccone, P. Caccin, M. Gallotta, G. Donvito, S. Falzoni, E. Palmieri, M. Pallaoro, R. Rappuoli, F. Di Virgilio, E. De Gregorio, C. Montecucco, and A. Seubert The adjuvant MF59 induces ATP release from muscle that potentiates response to vaccination Proc. Natl. Acad. Sci. U. S. A. 110 2013 21095 21100
92. S. Calabro, E. Tritto, A. Pezzotti, M. Taccone, A. Muzzi, S. Bertholet, E. De Gregorio, D.T. O'Hagan, B. Baudner, and A. Seubert The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect Vaccine 31 2013 3363 3369
93. R.C. Anderson, C.B. Fox, T.S. Dutill, N. Shaverdian, T.L. Evers, G.R. Poshusta, J. Chesko, R.N. Coler, M. Friede, S.G. Reed, and T.S. Vedvick Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations Colloids Surf. B: Biointerfaces 75 2010 123 132
94. R.N. Coler, S. Bertholet, M. Moutaftsi, J.A. Guderian, H.P. Windish, S.L. Baldwin, E.M. Laughlin, M.S. Duthie, C.B. Fox, D. Carter, M. Friede, T.S. Vedvick, and S.G. Reed Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant PLoS One 6 2011 e16333
95. M.A. Arias, G.A. Van Roey, J.S. Tregoning, M. Moutaftsi, R.N. Coler, H.P. Windish, S.G. Reed, D. Carter, and R.J. Shattock Glucopyranosyl lipid adjuvant (GLA), a synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140 PLoS One 7 2012 e41144
96. C.H. Clegg, R. Roque, N. Van Hoeven, L. Perrone, S.L. Baldwin, J.A. Rininger, R.A. Bowen, and S.G. Reed Adjuvant solution for pandemic influenza vaccine production Proc. Natl. Acad. Sci. U. S. A. 109 2012 17585 17590
97. M.T. Orr, C.B. Fox, S.L. Baldwin, S.J. Sivananthan, E. Lucas, S. Lin, T. Phan, J.J. Moon, T.S. Vedvick, S.G. Reed, and R.N. Coler Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis J. Control. Release 172 2013 190 200
98. C.B. Fox, S.L. Baldwin, M.S. Duthie, S.G. Reed, and T.S. Vedvick Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions Vaccine 29 2011 9563 9572
99. S. Lousada-Dietrich, P.S. Jogdand, S. Jepsen, V.V. Pinto, S.B. Ditlev, M. Christiansen, S.O. Larsen, C.B. Fox, V.S. Raman, R.F. Howard, T.S. Vedvick, G. Ireton, D. Carter, S.G. Reed, and M. Theisen A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2 - a GLURP-MSP3 fusion protein malaria vaccine candidate Vaccine 29 2011 3284 3292
100. S.L. Baldwin, N. Shaverdian, Y. Goto, M.S. Duthie, V.S. Raman, T. Evers, F. Mompoint, T.S. Vedvick, S. Bertholet, R.N. Coler, and S.G. Reed Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion Vaccine 27 2009 5956 5963
101. M.S. Duthie, L.H. Sampaio, R.M. Oliveira, V.S. Raman, J. O'Donnell, H.R. Bailor, G.C. Ireton, A.L. Sousa, M.M. Stefani, and S.G. Reed Development and pre-clinical assessment of a 73 kD chimeric fusion protein as a defined sub-unit vaccine for leprosy Vaccine 31 2013 813 819
102. A. Wack, B.C. Baudner, A.K. Hilbert, I. Manini, S. Nuti, S. Tavarini, H. Scheffczik, M. Ugozzoli, M. Singh, J. Kazzaz, E. Montomoli, G. Del Giudice, R. Rappuoli, and D.T. O'Hagan Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice Vaccine 26 2008 552 561
103. B.C. Baudner, V. Ronconi, D. Casini, M. Tortoli, J. Kazzaz, M. Singh, L.D. Hawkins, A. Wack, and D.T. O'Hagan MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020) Pharm. Res. 26 2009 1477 1485
104. G. Ott, M. Singh, J. Kazzaz, M. Briones, E. Soenawan, M. Ugozzoli, and D.T. O'Hagan A cationic sub-micron emulsion (MF59/DOTAP) is an effective delivery system for DNA vaccines J. Control. Release 79 2002 1 5 (Pubitemid 34164157)
105. D.T. O'Hagan, M. Singh, J. Kazzaz, M. Ugozzoli, M. Briones, J. Donnelly, and G. Ott Synergistic adjuvant activity of immunostimulatory DNA and oil/water emulsions for immunization with HIV p55 gag antigen Vaccine 20 2002 3389 3398 (Pubitemid 35245822)
106. L. Brito, M. Chan, C. Shaw, A. Hekele, T. Carsillo, M. Schafer, J. Archer, A. Seubert, G. Otten, C. Beard, A. Dey, A.E. Lilja, N.M. Valiante, P. Mason, C.W. Mandl, S. Barnett, P.R. Dormitzer, J.B. Ulmer, M. Singh, D. O'Hagan, and A. Geall A Cationic Nanoemulsion for the Delivery of Next Generation RNA Vaccines Under Revision 2014
107. V. Filipe, A. Hawe, and W. Jiskoot Critical evaluation of nanoparticle tracking analysis (NTA) by nanosight for the measurement of nanoparticles and protein aggregates Pharm. Res. 27 2010 796 810
108. V. Klang, C. Valenta, and N.B. Matsko Analytical electron microscopy for characterization of fluid or semi-solid multiphase systems containing nanoparticulate material Pharmaceutics 5 2013 115 126
109. A.G. Allison, and G. Gregoriadis Liposomes as immunological adjuvants Nature 252 1974 252
110. S. Pichyangkul, M. Gettayacamin, R.S. Miller, J.A. Lyon, E. Angov, P. Tongtawe, D.L. Ruble, D.G. Heppner Jr., K.E. Kester, W.R. Ballou, C.L. Diggs, G. Voss, J.D. Cohen, and D.S. Walsh Pre-clinical evaluation of the malaria vaccine candidate P. falciparum MSP1(42) formulated with novel adjuvants or with alum Vaccine 22 2004 3831 3840 (Pubitemid 39208744)
111. J. Davidsen, I. Rosenkrands, D. Christensen, A. Vangala, D. Kirby, Y. Perrie, E.M. Agger, and P. Andersen Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6′-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses Biochim. Biophys. Acta 1718 2005 22 31 (Pubitemid 41698893)
112. B. Banerji, and C.R. Alving Lipid A from endotoxin: antigenic activities of purified fractions in liposomes J. Immunol. 123 1979 2558 2562 (Pubitemid 10218049)
113. K.E. Kester, J.F. Cummings, O. Ofori-Anyinam, C.F. Ockenhouse, U. Krzych, P. Moris, R. Schwenk, R.A. Nielsen, Z. Debebe, E. Pinelis, L. Juompan, J. Williams, M. Dowler, V.A. Stewart, R.A. Wirtz, M.C. Dubois, M. Lievens, J. Cohen, W.R. Ballou, and D.G. Heppner Jr. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS, S/AS01B and RTS, S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection J. Infect. Dis. 200 2009 337 346
114. J.A. Stoute, M. Slaoui, D.G. Heppner, P. Momin, K.E. Kester, P. Desmons, B.T. Wellde, N. Garcon, U. Krzych, M. Marchand RTS,S Malaria Vaccine Evaluation Group A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria N. Engl. J. Med. 336 1997 86 91 (Pubitemid 27020884)
115. P. Vandepapeliere, Vaccine compositions comprising a saponin adjuvant. In: 13/020 (Ed.) US patent application no. 2011 Feb 3; Publ No. US 20/0206758, 25 Aug 2011, US patent application, 2011.
116. J.A. Regules, J.F. Cummings, and C.F. Ockenhouse The RTS,S vaccine candidate for malaria Expert. Rev. Vaccines 10 2011 589 599
117. A.J. Birkett PATH Malaria Vaccine Initiative (MVI): perspectives on the status of malaria vaccine development Hum. Vaccin. 6 2010 139 145
118. C.R. Kensil, and R. Kammer QS-21: a water-soluble triterpene glycoside adjuvant Expert. Opin. Investig. Drugs 7 1998 1475 1482 (Pubitemid 28408808)
119. P.M. Momin, N. Garcon, Vaccines, in: 08/663 (Ed.) US patent application no. 20 Dec 1994, 1994.
120. C.B. Fox, M. Moutaftsi, J. Vergara, A.L. Desbien, G.I. Nana, T.S. Vedvick, R.N. Coler, and S.G. Reed TLR4 ligand formulation causes distinct effects on antigen-specific cell-mediated and humoral immune responses Vaccine 31 2013 5848 5855
121. J. Szebeni, P. Bedocs, Z. Rozsnyay, Z. Weiszhar, R. Urbanics, L. Rosivall, R. Cohen, O. Garbuzenko, G. Bathori, M. Toth, R. Bunger, and Y. Barenholz Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and AmBisome Nanomedicine 8 2012 176 184
122. D.S. Watson, A.N. Endsley, and L. Huang Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens Vaccine 30 2012 2256 2272
123. E. Shahum, and H.M. Therien Immunopotentiation of the humoral response by liposomes: encapsulation versus covalent linkage Immunology 65 1988 315 317
124. D. Christensen, E.M. Agger, L.V. Andreasen, D. Kirby, P. Andersen, and Y. Perrie Liposome-based cationic adjuvant formulations (CAF): past, present, and future J. Liposome Res. 19 2009 2 11
125. J.J. Moon, H. Suh, A. Bershteyn, M.T. Stephan, H. Liu, B. Huang, M. Sohail, S. Luo, S.H. Um, H. Khant, J.T. Goodwin, J. Ramos, W. Chiu, and D.J. Irvine Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses Nat. Mater. 10 2011 243 251
126. V. D'Acremont, C. Herzog, and B. Genton Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in the elderly J. Travel Med. 13 2006 78 83
127. R. Gluck, R. Mischler, S. Brantschen, M. Just, B. Althaus, and S.J. Cryz Jr. Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A J. Clin. Invest. 90 1992 2491 2495 (Pubitemid 23010069)
128. V. Baldo, T. Baldovin, M. Pellegrini, G. Angiolelli, S. Majori, A. Floreani, M.C. Busana, C. Bertoncello, and R. Trivello Immunogenicity of three different influenza vaccines against homologous and heterologous strains in nursing home elderly residents Clin. Dev. Immunol. 2010 2010 517198
129. P.A. Bovier Epaxal: a virosomal vaccine to prevent hepatitis A infection Expert. Rev. Vaccines 7 2008 1141 1150
130. L. Bungener, K. Serre, L. Bijl, L. Leserman, J. Wilschut, T. Daemen, and P. Machy Virosome-mediated delivery of protein antigens to dendritic cells Vaccine 20 2002 2287 2295 (Pubitemid 34497039)
131. S.D. Litwin, and J.M. Singer The adjuvant action of latex particulate carriers J. Immunol. 95 1965 1147 1152
132. S.J. Challacombe, D. Rahman, H. Jeffery, S.S. Davis, and D.T. O'Hagan Enhanced secretory IgA and systemic IgG antibody responses after oral immunization with biodegradable microparticles containing antigen Immunology 76 1992 164 168
133. I. Preis, and R.S. Langer A single-step immunization by sustained antigen release J. Immunol. Methods 28 1979 193 197 (Pubitemid 9221935)
134. A.S. Hoffman The origins and evolution of "controlled" drug delivery systems J. Control. Release 132 2008 153 163
135. S. Jain, D.T. O'Hagan, and M. Singh The long-term potential of biodegradable poly(lactide-co-glycolide) microparticles as the next-generation vaccine adjuvant Expert. Rev. Vaccines 10 2011 1731 1742
136. V. Milacic, A.B. Bailey, D. O'Hagan, and P. Schwendeman Injectable PLGA systems for delivery of vaccine in: long acting injections and implants Adv. Deliv. Sci. Technol. 2012 429
137. M. Singh, J. Kazzaz, J. Chesko, E. Soenawan, M. Ugozzoli, M. Giuliani, M. Pizza, R. Rappouli, and D.T. O'Hagan Anionic microparticles are a potent delivery system for recombinant antigens from Neisseria meningitidis serotype B J. Pharm. Sci. 93 2004 273 282 (Pubitemid 38174250)
138. M. Singh, J. Chesko, J. Kazzaz, M. Ugozzoli, E. Kan, I. Srivastava, and D.T. O'Hagan Adsorption of a novel recombinant glycoprotein from HIV (Env gp120dV2 SF162) to anionic PLG microparticles retains the structural integrity of the protein, whereas encapsulation in PLG microparticles does not Pharm. Res. 21 2004 2148 2152 (Pubitemid 40568427)
139. J. Kazzaz, M. Singh, M. Ugozzoli, J. Chesko, E. Soenawan, and D.T. O'Hagan Encapsulation of the immune potentiators MPL and RC529 in PLG microparticles enhances their potency J. Control. Release 110 2006 566 573 (Pubitemid 43168189)
140. H. Xie, I. Gursel, B.E. Ivins, M. Singh, D.T. O'Hagan, J.B. Ulmer, and D.M. Klinman CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine Infect. Immun. 73 2005 828 833 (Pubitemid 40165739)
141. S. Jain, P. Malyala, M. Pallaoro, M. Giuliani, H. Petersen, D.T. O'Hagan, and M. Singh A two-stage strategy for sterilization of poly(lactide-co- glycolide) particles by gamma-irradiation does not impair their potency for vaccine delivery J. Pharm. Sci. 100 2011 646 654
142. A. Moore, P. McGuirk, S. Adams, W.C. Jones, J.P. McGee, D.T. O'Hagan, and K.H. Mills Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8 + cytotoxic T lymphocytes and CD4 + Th1 cells Vaccine 13 1995 1741 1749 (Pubitemid 26013110)
143. G.R. Otten, M. Schaefer, B. Doe, H. Liu, I. Srivastava, J. Megede, J. Kazzaz, Y. Lian, M. Singh, M. Ugozzoli, D. Montefiori, M. Lewis, D.A. Driver, T. Dubensky, J.M. Polo, J. Donnelly, D.T. O'Hagan, S. Barnett, and J.B. Ulmer Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteins J. Virol. 79 2005 8189 8200 (Pubitemid 40853522)
144. S.P. Kasturi, I. Skountzou, R.A. Albrecht, D. Koutsonanos, T. Hua, H.I.
145. J. Wendorf, M. Singh, J. Chesko, J. Kazzaz, E. Soewanan, M. Ugozzoli, and D. O'Hagan A practical approach to the use of nanoparticles for vaccine delivery J. Pharm. Sci. 95 2006 2738 2750 (Pubitemid 46093180)
146. J. Wendorf, J. Chesko, J. Kazzaz, M. Ugozzoli, M. Vajdy, D. O'Hagan, and M. Singh A comparison of anionic nanoparticles and microparticles as vaccine delivery systems Hum. Vaccin. 4 2008 44 49 (Pubitemid 351785260)
147. J.P. Rolland, B.W. Maynor, L.E. Euliss, A.E. Exner, G.M. Denison, and J.M. DeSimone Direct fabrication and harvesting of monodisperse, shape-specific nanobiomaterials J. Am. Chem. Soc. 127 2005 10096 10100 (Pubitemid 40995455)
148. A.L. Galloway, A. Murphy, J.M. DeSimone, J. Di, J.P. Herrmann, M.E. Hunter, J.P. Kindig, F.J. Malinoski, M.A. Rumley, D.M. Stoltz, T.S. Templeman, and B. Hubby Development of a nanoparticle-based influenza vaccine using the PRINT technology Nanomedicine 9 2013 523 531
149. N.F. Eng, S. Garlapati, V. Gerdts, A. Potter, L.A. Babiuk, and G.K. Mutwiri The potential of polyphosphazenes for delivery of vaccine antigens and immunotherapeutic agents Curr. Drug Deliv. 7 2010 13 20
150. Y. Honda-Okubo, F. Saade, and N. Petrovsky Advax, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses Vaccine 30 2012 5373 5381
151. H.C. Arca, M. Gunbeyaz, and S. Senel Chitosan-based systems for the delivery of vaccine antigens Expert. Rev. Vaccines 8 2009 937 953
152. X. Li, X. Kong, S. Shi, X. Zheng, G. Guo, Y. Wei, and Z. Qian Preparation of alginate coated chitosan microparticles for vaccine delivery BMC Biotechnol. 8 2008 89
153. C. Wang, Q. Ge, D. Ting, D. Nguyen, H.R. Shen, J. Chen, H.N. Eisen, J. Heller, R. Langer, and D. Putnam Molecularly engineered poly(ortho ester) microspheres for enhanced delivery of DNA vaccines Nat. Mater. 3 2004 190 196
154. B. Morein, B. Sundquist, S. Hoglund, K. Dalsgaard, and A. Osterhaus Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses Nature 308 1984 457 460 (Pubitemid 14130919)
155. D. Drane, C. Gittleson, J. Boyle, and E. Maraskovsky ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines Expert. Rev. Vaccines 6 2007 761 772 (Pubitemid 47607851)
156. M. Schnurr, M. Orban, N.C. Robson, A. Shin, H. Braley, D. Airey, J. Cebon, E. Maraskovsky, and S. Endres ISCOMATRIX adjuvant induces efficient cross-presentation of tumor antigen by dendritic cells via rapid cytosolic antigen delivery and processing via tripeptidyl peptidase II J. Immunol. 182 2009 1253 1259
157. N.K. Polakos, D. Drane, J. Cox, P. Ng, M.J. Selby, D. Chien, D.T. O'Hagan, M. Houghton, and X. Paliard Characterization of hepatitis C virus core-specific immune responses primed in rhesus macaques by a nonclassical ISCOM vaccine J. Immunol. 166 2001 3589 3598 (Pubitemid 33117365)
158. R.G. Windon, P.J. Chaplin, P. McWaters, M. Tavarnesi, M. Tzatzaris, W.G. Kimpton, R.N. Cahill, L. Beezum, A. Coulter, D. Drane, A. Sjolander, M. Pearse, J.P. Scheerlinck, and J.M. Tennent Local immune responses to influenza antigen are synergistically enhanced by the adjuvant ISCOMATRIX Vaccine 20 2001 490 497 (Pubitemid 32973793)
159. M.J. Copland, T. Rades, and N.M. Davies Hydration of lipid films with an aqueous solution of Quil A: a simple method for the preparation of immune-stimulating complexes Int. J. Pharm. 196 2000 135 139 (Pubitemid 30105729)
160. V.V. Pinto, A. Salanti, L.M. Joergensen, M. Dahlback, M. Resende, S.B. Ditlev, E.M. Agger, D.E. Arnot, T.G. Theander, and M.A. Nielsen The effect of adjuvants on the immune response induced by a DBL4varepsilon-ID4 VAR2CSA based Plasmodium falciparum vaccine against placental malaria Vaccine 30 2012 572 579
161. A. Fomsgaard, I. Karlsson, G. Gram, C. Schou, S. Tang, P. Bang, I. Kromann, P. Andersen, and L.V. Andreasen Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01 Vaccine 29 2011 7067 7074
162. A.W. Olsen, P. Andersen, and F. Follmann Characterization of protective immune responses promoted by human antigen targets in a urogenital Chlamydia trachomatis mouse model Vaccine 32 6 2014 Feb 3 685 692
163. I. Rosenkrands, C. Vingsbo-Lundberg, T.J. Bundgaard, T. Lindenstrom, V. Enouf, S. van der Werf, P. Andersen, and E.M. Agger Enhanced humoral and cell-mediated immune responses after immunization with trivalent influenza vaccine adjuvanted with cationic liposomes Vaccine 29 2011 6283 6291
164. D. Christensen, T. Lindenstrom, G. van de Wijdeven, P. Andersen, and E.M. Agger Syringe free vaccination with CAF01 Adjuvated Ag85B-ESAT-6 in Bioneedles provides strong and prolonged protection against tuberculosis PLoS One 5 2010 e15043
165. D. Gall The adjuvant activity of aliphatic nitrogenous bases Immunology 11 1966 369 386
166. M. Hamborg, R. Kramer, C.E. Schante, E.M. Agger, D. Christensen, L. Jorgensen, C. Foged, and C.R. Middaugh The physical stability of the recombinant tuberculosis fusion antigens h1 and h56 J. Pharm. Sci. 102 2013 3567 3578
167. D. Christensen, M. Henriksen-Lacey, A.T. Kamath, T. Lindenstrom, K.S. Korsholm, J.P. Christensen, A.F. Rochat, P.H. Lambert, P. Andersen, C.A. Siegrist, Y. Perrie, and E.M. Agger A cationic vaccine adjuvant based on a saturated quaternary ammonium lipid have different in vivo distribution kinetics and display a distinct CD4 T cell-inducing capacity compared to its unsaturated analog J. Control. Release 160 2012 468 476
168. R. Kaur, V.W. Bramwell, D.J. Kirby, and Y. Perrie Pegylation of DDA:TDB liposomal adjuvants reduces the vaccine depot effect and alters the Th1/Th2 immune responses J. Control. Release 158 2012 72 77
169. M. Henriksen-Lacey, D. Christensen, V.W. Bramwell, T. Lindenstrom, E.M. Agger, P. Andersen, and Y. Perrie Comparison of the depot effect and immunogenicity of liposomes based on dimethyldioctadecylammonium (DDA), 3beta-[N-(N′,N′-dimethylaminoethane)carbomyl] cholesterol (DC-Chol), and 1,2-Dioleoyl-3-trimethylammonium propane (DOTAP): prolonged liposome retention mediates stronger Th1 responses Mol. Pharm. 8 2011 153 161
170. M. Henriksen-Lacey, A. Devitt, and Y. Perrie The vesicle size of DDA:TDB liposomal adjuvants plays a role in the cell-mediated immune response but has no significant effect on antibody production J. Control. Release 154 2011 131 137
171. J.H. Fritz, S. Brunner, M.L. Birnstiel, M. Buschle, A. Gabain, F. Mattner, and W. Zauner The artificial antimicrobial peptide KLKLLLLLKLK induces predominantly a TH2-type immune response to co-injected antigens Vaccine 22 2004 3274 3284 (Pubitemid 39078743)
172. C. Schellack, K. Prinz, A. Egyed, J.H. Fritz, B. Wittmann, M. Ginzler, G. Swatosch, W. Zauner, C. Kast, S. Akira, A. von Gabain, M. Buschle, and K. Lingnau IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses Vaccine 24 2006 5461 5472 (Pubitemid 43831376)
173. M.C. Aichinger, M. Ginzler, J. Weghuber, L. Zimmermann, K. Riedl, G. Schutz, E. Nagy, A. von Gabain, R. Schweyen, and T. Henics Adjuvating the adjuvant: facilitated delivery of an immunomodulatory oligonucleotide to TLR9 by a cationic antimicrobial peptide in dendritic cells Vaccine 29 2011 426 436
174. L.L. Farrell, J. Pepin, C. Kucharski, X. Lin, Z. Xu, and H. Uludag A comparison of the effectiveness of cationic polymers poly-L-lysine (PLL) and polyethylenimine (PEI) for non-viral delivery of plasmid DNA to bone marrow stromal cells (BMSC) Eur. J. Pharm. Biopharm. 65 2007 388 397
175. A. Szabo, P. Gogolak, K. Pazmandi, K. Kis-Toth, K. Riedl, B. Wizel, K. Lingnau, A. Bacsi, B. Rethi, and E. Rajnavolgyi The two-component adjuvant IC31(R) boosts type i interferon production of human monocyte-derived dendritic cells via ligation of endosomal TLRs PLoS One 8 2013 e55264
176. C. Bode, G. Zhao, F. Steinhagen, T. Kinjo, and D.M. Klinman CpG DNA as a vaccine adjuvant Expert. Rev. Vaccines 10 2011 499 511
177. S. Vecchi, S. Bufali, T. Uno, T. Wu, L. Arcidiacono, S. Filippini, F. Rigat, and D. O'Hagan Conjugation of a TLR7 agonist and antigen enhances protection in the S. pneumoniae murine infection model Eur. J. Pharm. Biopharm. 87 2 2014 Jul 310 317
178. T. Querec, S. Bennouna, S. Alkan, Y. Laouar, K. Gorden, R. Flavell, S. Akira, R. Ahmed, and B. Pulendran Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity J. Exp. Med. 203 2006 413 424 (Pubitemid 43290850)
179. W.I. Lencer, and U.H. von Andrian Eliciting mucosal immunity N. Engl. J. Med. 365 2011 1151 1153
180. L. Kjer-Nielsen, O. Patel, A.J. Corbett, J. Le Nours, B. Meehan, L. Liu, M. Bhati, Z. Chen, L. Kostenko, R. Reantragoon, N.A. Williamson, A.W. Purcell, N.L. Dudek, M.J. McConville, R.A. O'Hair, G.N. Khairallah, D.I. Godfrey, D.P. Fairlie, J. Rossjohn, and J. McCluskey MR1 presents microbial vitamin B metabolites to MAIT cells Nature 491 2012 717 723
181. N. Garcon, D.W. Vaughn, and A.M. Didierlaurent Development and evaluation of AS03, an adjuvant system containing alpha-tocopherol and squalene in an oil-in-water emulsion Expert. Rev. Vaccines 11 2012 349 366
182. V.R. Roman, K.J. Jensen, S.S. Jensen, C. Leo-Hansen, S. Jespersen, D. da Silva Te, C.M. Rodrigues, C.M. Janitzek, L. Vinner, T.L. Katzenstein, P. Andersen, I. Kromann, L.V. Andreasen, I. Karlsson, and A. Fomsgaard Therapeutic vaccination using cationic liposome-adjuvanted HIV type 1 peptides representing HLA-supertype-restricted subdominant T cell epitopes: safety, immunogenicity, and feasibility in Guinea-Bissau AIDS Res. Hum. Retrovir. 29 2013 1504 1512
183. A.S. Levine, and H.B. Levy Phase I-II trials of poly IC stabilized with poly-l-lysine Cancer Treat. Rep. 62 1978 1907 1912 (Pubitemid 9120849)
184. S. Daayana, E. Elkord, U. Winters, M. Pawlita, R. Roden, P.L. Stern, and H.C. Kitchener Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia Br. J. Cancer 102 2010 1129 1136
185. H. Behzad, A.L. Huckriede, L. Haynes, B. Gentleman, K. Coyle, J.C. Wilschut, T.R. Kollmann, S.G. Reed, and J.E. McElhaney GLA-SE, a synthetic toll-like receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults J. Infect. Dis. 205 2012 466 473
186. A. McKenzie, M. Watt, and C. Gittleson ISCOMATRIX() vaccines: safety in human clinical studies Hum. Vaccin. 6 2010
187. R. Hutchison Is petroleum emulsion of any nutritive value? Br. Med. J. 1 1899 724
188. F. Cabot Report of experimental work on the dilution method of immunization from rabies J. Exp. Med. 4 1899 181 188
189. D.F. Driscoll Lipid injectable emulsions: 2006 Nutr. Clin. Pract. 21 2006 381 386
190. J.M. Mirtallo, J.F. Dasta, K.C. Kleinschmidt, and J. Varon State of the art review: intravenous fat emulsions: current applications, safety profile, and clinical implications Ann. Pharmacother. 44 2010 688 700
191. A.D. Bangham, and R.W. Horne Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope J. Mol. Biol. 8 1964 660 668
192. R. Mischler, and I.C. Metcalfe Inflexal V a trivalent virosome subunit influenza vaccine: production Vaccine 20 Suppl. 5 2002 B17 B23 (Pubitemid 35435392)